BioSpace News Archive

Encouraging preliminary results about the iBiopsy® clinical development plan on liver cancer and the technological methods therein Development of a fibrosis biomarker from CT scan imaging A better performing biomarker compared to existing imaging biomarkers

National Health Investors, Inc. (NYSE:NHI) announced today that it will pay its second quarter dividend of $1.1025 per common share on August 7, 2020 to shareholders of record as of June 30, 2020.

Pharma-Bio Serv, Inc. (“Pharma-Bio Serv” or the “Company”) (OTCQB:PBSV), a compliance, project management and technology transfer support consulting firm that provides services to the pharmaceutical, biotechnology, chemical, medical device, cosmetic, food and allied products industries, today announced revenues for the three and six months ended April 30, 2020 were $5,648,000 and $10,261,000,

AOPEN, a global technology company that specializes in smart products and services for cloud-based applications, is proud to announce the launch of the AOPEN Heat Finder Thermal Imaging Solution − a dual-camera system that quickly and accurately detects elevated body temperatures.

Alnylam Pharmaceuticals, Inc., the leading RNAi therapeutics company, announced that management will present a company overview at the Bank of America Securities 2020 Napa Biopharma Conference on Wednesday, June 24, 2020 at 10:30 am PT via webcast.

Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a specialty pharmaceutical company committed to being the leader in responsible pain management, today announced that it has been named one of Boston Business Journal’s 2020 Best Places to Work.

Naviswiss AG, a medical technology company based in Denver, Colorado, with headquarters in Brugg, Switzerland, receives FDA Clearance on June 10, 2020, for their new navigation technology for hip replacement surgery.

Brickell Biotech, Inc., a clinical-stage pharmaceutical company focused on developing innovative and differentiated prescription therapeutics for the treatment of debilitating skin diseases, announced the pricing of an underwritten public offering of 17,500,000 shares of common stock or common stock equivalents and investor warrants to purchase up to an aggregate of 17,500,000 shares of common stock.

Provention Bio, Inc., a biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, announced the pricing of its previously announced underwritten public offering of 6,600,000 shares of its common stock at a public offering price of $14.50 per share.

Protagonist Therapeutics, Inc. announced that the U.S. Food and Drug Administration has granted Orphan Drug Designation for PTG-300 for the treatment of polycythemia vera.